Stock Track | Kymera Therapeutics Plunges After Q3 Revenue Miss and Strategic Pivot

Stock Track

2024/10/31

Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted 6.13% on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.

The biopharmaceutical company reported quarterly revenue of $3.74 million, missing analyst consensus estimates of $10.36 million by a significant 63.9%. This represented a 20.9% year-over-year decline, sending the stock into a tailspin as investors reacted to the disappointing top-line performance.

While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1167922395"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167922395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167922395?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167922395","market":"hk","top_or_hot":-1,"title":"Stock Track | Kymera Therapeutics Plunges After Q3 Revenue Miss and Strategic Pivot","media":"Stock Track","content":"<p>Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted 6.13% on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.</p>\n\n<p>The biopharmaceutical company reported quarterly revenue of $3.74 million, missing analyst consensus estimates of $10.36 million by a significant 63.9%. This represented a 20.9% year-over-year decline, sending the stock into a tailspin as investors reacted to the disappointing top-line performance.</p>\n\n<p>While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kymera Therapeutics Plunges After Q3 Revenue Miss and Strategic Pivot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kymera Therapeutics Plunges After Q3 Revenue Miss and Strategic Pivot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-31 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted 6.13% on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.</p>\n\n<p>The biopharmaceutical company reported quarterly revenue of $3.74 million, missing analyst consensus estimates of $10.36 million by a significant 63.9%. This represented a 20.9% year-over-year decline, sending the stock into a tailspin as investors reacted to the disappointing top-line performance.</p>\n\n<p>While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1167922395","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167922395","pubTimestamp":1730381646,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Kymera Therapeutics, Inc.  plummeted 6.13% on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.The biopharmaceutical company reported quarterly revenue of $3.74 million, missing analyst consensus estimates of $10.36 million by a significant 63.9%. This represented a 20.9% year-over-year decline, sending the stock into a tailspin as investors reacted to the disappointing top-line performance.While Kymera beat earnings ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"Kymera Therapeutics第三季度收入未达预期和战略转向后股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted 6.13% on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.\nThe biopharmaceutical company reported quarterly revenue of $3.74 million, missing analyst consensus estimates of $10.36 million by a significant 63.9%. This represented a 20.9% year-over-year decline, sending the stock into a tailspin as investors reacted to the disappointing top-line performance.\nWhile Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}